MX2010008637A - Derivado de fenilpirrol novedoso. - Google Patents

Derivado de fenilpirrol novedoso.

Info

Publication number
MX2010008637A
MX2010008637A MX2010008637A MX2010008637A MX2010008637A MX 2010008637 A MX2010008637 A MX 2010008637A MX 2010008637 A MX2010008637 A MX 2010008637A MX 2010008637 A MX2010008637 A MX 2010008637A MX 2010008637 A MX2010008637 A MX 2010008637A
Authority
MX
Mexico
Prior art keywords
group
groups
mono
alkyl
substituted independently
Prior art date
Application number
MX2010008637A
Other languages
English (en)
Inventor
Hideki Kobayashi
Akihiro Furukawa
Takehiro Fukuzaki
Yukari Onishi
Takeshi Honda
Yumi Matsui
Masahiro Konishi
Tetsuyoshi Matsufuji
Kenjiro Ueda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2010008637A publication Critical patent/MX2010008637A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto que tiene una actividad activadora de glucocinasa superior y está representado por la fórmula general (I), y las sales farmacológicamente aceptables del mismo: (ver fórmula (I)) [en donde: A representa, por ejemplo, un átomo de oxigeno o un átomo de azufre, R1 representa, por ejemplo, un grupo alquilo de C1-C6, un grupo alcoxi de C1-C6 o un grupo alquilo de C1-C6 halogenado, A y R1 junto con el átomo de carbono al que están unidos forman un grupo heterocíclico que puede estar sustituido con 1 a 3 grupos seleccionados independientemente del conjunto de sustituyentes a, R2 representa un grupo fenilo que puede estar sustituido con 1 a 5 grupos seleccionados independientemente del conjunto de sustituyentes a, o un grupo heterocíclico que puede estar sustituido con 1 a 3 grupos seleccionados independientemente del conjunto de sustituyentes a, R3 representa un grupo hidroxi o un grupo alcoxi de C1-C6, y el conjunto de sustituyentes a consiste, por ejemplo, en un átomo de halógeno, un grupo alquilo de C1-C6, un grupo alquilo de C1-C6 sustituido con 1 o 2 grupos hidroxi, un grupo alquilsulfonhlo de C1-C6 y un grupo representado por la fórmula -V-NR5R6 (en donde V representa un grupo carbonilo o un grupo sulfonilo, y R5 y R6 pueden ser iguales o diferentes entre sí y representan respectivamente un átomo de hidrógeno o un grupo alquilo de C1-C6, o R5 y R6, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo saturado de 4 a 6 miembros que puede estar sustituido con 1 o 2 grupos seleccionados independientemente de un grupo alquilo de C1-C6 y un grupo hidroxi, y el heterociclo saturado de 4 a 6 miembros también puede contener un átomo de oxígeno o un átomo de nitrógeno)].
MX2010008637A 2008-02-06 2009-02-04 Derivado de fenilpirrol novedoso. MX2010008637A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008026519 2008-02-06
JP2008314479 2008-12-10
PCT/JP2009/051834 WO2009099080A1 (ja) 2008-02-06 2009-02-04 新規フェニルピロール誘導体

Publications (1)

Publication Number Publication Date
MX2010008637A true MX2010008637A (es) 2010-08-30

Family

ID=40952154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008637A MX2010008637A (es) 2008-02-06 2009-02-04 Derivado de fenilpirrol novedoso.

Country Status (21)

Country Link
US (2) US8017610B2 (es)
EP (1) EP2239253B1 (es)
JP (2) JP4503101B2 (es)
KR (1) KR20100118979A (es)
CN (1) CN102015637B (es)
AU (1) AU2009211718B2 (es)
BR (1) BRPI0908124A2 (es)
CA (1) CA2715143C (es)
CO (1) CO6331462A2 (es)
DK (1) DK2239253T3 (es)
ES (1) ES2425190T3 (es)
HK (1) HK1148740A1 (es)
IL (1) IL207372A0 (es)
MX (1) MX2010008637A (es)
MY (1) MY150269A (es)
NZ (1) NZ587126A (es)
PL (1) PL2239253T3 (es)
PT (1) PT2239253E (es)
RU (1) RU2470917C2 (es)
TW (1) TWI432429B (es)
WO (1) WO2009099080A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082601A1 (ja) * 2009-01-16 2010-07-22 第一三共株式会社 新規２，５－二置換ピロール誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011122458A1 (ja) * 2010-03-29 2011-10-06 第一三共株式会社 含窒素芳香環化合物
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201247659A (en) * 2011-04-27 2012-12-01 Daiichi Sankyo Co Ltd Crystals of phenylpyrrole derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018019758A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019770A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyridine compounds
EP3275877A1 (en) 2016-07-28 2018-01-31 Basf Se Herbicidal pyridine compounds
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN112707898A (zh) * 2020-12-21 2021-04-27 徐新杰 一种杂芳基取代的吡嗪衍生物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
EP1169312B1 (en) 1999-03-29 2004-10-06 F. Hoffmann-La Roche Ag Glucokinase activators
JP4419571B2 (ja) 2002-03-26 2010-02-24 萬有製薬株式会社 新規アミノベンズアミド誘導体
CA2516407C (en) 2003-02-26 2013-07-09 Banyu Pharmaceutical Co., Ltd. Heteroarylcarbamoylbenzene derivatives
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
CA2551324C (en) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2005080359A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
GB0403593D0 (en) * 2004-02-18 2004-03-24 Astrazeneca Ab Compounds
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
CN1950361A (zh) 2004-05-10 2007-04-18 霍夫曼-拉罗奇有限公司 用于治疗肥胖的吡咯或咪唑酰胺化合物
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
EP1889842A4 (en) * 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
CA2613303C (en) 2005-07-11 2012-06-19 Mitsubishi Tanabe Pharma Corporation An oxime derivative for use as a glucokinase activator
WO2007031739A1 (en) 2005-09-16 2007-03-22 Astrazeneca Ab Heterobicyclic compounds as glucokinase activators
CA2623958C (en) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
CN101321747A (zh) 2005-11-01 2008-12-10 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类
CA2628259A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
MY148985A (en) 2006-03-24 2013-06-28 Array Biopharma Inc 2-aminopyridine analogs as glucokinase activators
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical HETEROCYCLIC COMPOUND WITH FIVE NITROGEN CHAINS

Also Published As

Publication number Publication date
KR20100118979A (ko) 2010-11-08
AU2009211718A1 (en) 2009-08-13
DK2239253T3 (da) 2013-09-23
JPWO2009099080A1 (ja) 2011-05-26
CA2715143A1 (en) 2009-08-13
CO6331462A2 (es) 2011-10-20
US20110003787A1 (en) 2011-01-06
IL207372A0 (en) 2010-12-30
CN102015637A (zh) 2011-04-13
PL2239253T3 (pl) 2013-11-29
AU2009211718B2 (en) 2011-08-11
US20120022075A1 (en) 2012-01-26
EP2239253B1 (en) 2013-06-19
CN102015637B (zh) 2014-05-21
EP2239253A1 (en) 2010-10-13
HK1148740A1 (en) 2011-09-16
US8415359B2 (en) 2013-04-09
ES2425190T3 (es) 2013-10-14
JP5074545B2 (ja) 2012-11-14
TWI432429B (zh) 2014-04-01
JP2010163449A (ja) 2010-07-29
RU2470917C2 (ru) 2012-12-27
NZ587126A (en) 2011-12-22
CA2715143C (en) 2013-04-02
BRPI0908124A2 (pt) 2015-08-04
MY150269A (en) 2013-12-31
WO2009099080A1 (ja) 2009-08-13
EP2239253A4 (en) 2011-02-23
PT2239253E (pt) 2013-09-17
US8017610B2 (en) 2011-09-13
TW200938539A (en) 2009-09-16
RU2010136953A (ru) 2012-03-20
JP4503101B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
MX2010008637A (es) Derivado de fenilpirrol novedoso.
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MX2011008305A (es) Compuestos de piridazinona.
MY152972A (en) Azabicyclo compound and salt thereof
MX2009010024A (es) Nuevo compuesto de adenina.
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
WO2008108386A1 (ja) 医薬組成物
EA200870336A1 (ru) Полициклические производные циннамида
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
TN2011000422A1 (en) Benzofuran derivatives
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
RS53679B1 (en) FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES
MY169179A (en) Novel piperidine compound or salt thereof
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
IN2012DN00770A (es)
EA200900616A1 (ru) Ингибиторы ikk-бета серин-треонин протеинкиназы
IN2012DN00768A (es)
ES2439793T3 (es) Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
WO2007082262A3 (en) Novel compounds
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.

Legal Events

Date Code Title Description
FG Grant or registration